AbbVie Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

AbbVie hat ein Gesamteigenkapital von $8.0B und eine Gesamtverschuldung von $74.4B, wodurch sich der Verschuldungsgrad auf 924.1% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $148.9B bzw. $140.8B. AbbVie Das EBIT des Unternehmens beträgt $17.5B, so dass der Zinsdeckungsgrad 10.4 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $18.1B.

Wichtige Informationen

1,040.0%

Verhältnis von Schulden zu Eigenkapital

US$70.94b

Verschuldung

Zinsdeckungsgrad	10.1x
Bargeld	US$13.16b
Eigenkapital	US$6.82b
Gesamtverbindlichkeiten	US$135.12b
Gesamtvermögen	US$141.94b

Jüngste Berichte zur Finanzlage

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

Sep 06

Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly

May 21

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ABBVDie kurzfristigen Aktiva des Unternehmens ($33.8B) decken seine kurzfristigen Passiva ($41.9B) nicht.

Langfristige Verbindlichkeiten: ABBVDie kurzfristigen Vermögenswerte des Unternehmens ($33.8B) decken seine langfristigen Verbindlichkeiten ($93.2B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ABBVDie Nettoverschuldung im Verhältnis zum Eigenkapital (699.5%) wird als hoch angesehen.

Schulden abbauen: ABBV hatte vor 5 Jahren ein negatives Eigenkapital, ist jetzt aber positiv und hat sich somit verbessert.

Schuldendeckung: ABBVDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (26.3%).

Zinsdeckung: ABBVDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (10.4x Coverage) gut gedeckt.

AbbVie Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly

Recent updates

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Why AbbVie Remains One Of My Favorite Dividend Growers

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold US$12m worth of stock

Consensus EPS estimates fall by 10%

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

AbbVie: Growth Is Still A Better Choice

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Executive Chairman notifies of intention to sell stock

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie: A Hold Again (Rating Downgrade)

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) acquired Celsius Therapeutics, Inc. for $250 million.

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie: 5 Reasons That Make A Buy Case

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AbbVie's Q1: Positive Surprise

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie: Great To Be Proven Wrong - Still Not A Buy

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Executive VP & Chief Commercial Officer recently sold US$5.9m worth of stock

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie: Strong Cash Flow Growth Fuels Dividend Growth

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen